[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100117556":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":21,"centralContacts":25,"locations":35,"responsibleParty":54,"collaborators":57,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":30,"enrollmentInfo":70,"targetDuration":30,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":80,"overallStatus":38,"whyStopped":30,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"SEARCH Research Foundation","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"HAART","The proposed HAART regimen consists of:\n\n* 1 or 2 nucleoside\u002Fnucleotide analog reverse-transcriptase inhibitor (NRTI) class medications plus\n* Dolutegravir(DTG) 50 mg orally once daily",[12],"Drug: HAART",[14],{"type":15,"name":9,"description":16,"armGroupLabels":17,"otherNames":18},"DRUG","1 (lamivudine) or 2 (lamivudine + abacavir) nuceloside\u002Fnucleotide analog reverse-transcriptase inhibitor (NRTI) class medications once daily\n\nplus\n\ndolutegravir(DTG) 50 mg orally once daily",[9],[19,20],"Triumeq","Dovato",[22],{"name":23,"affiliation":5,"role":24},"Somchai Sriplienchan, MD, MPH","PRINCIPAL_INVESTIGATOR",[26,32],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Nitiya Chomchey, RN, PhD","CONTACT","66 82 899 4433",null,"nitiya.c@searchthailand.org",{"name":33,"role":28,"phone":30,"phoneExt":30,"email":34},"Tassanee Luekasemsuk, MSc","tassanee.l@searchthailand.org",[36],{"facility":37,"status":38,"city":39,"state":30,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Institute of HIV Research and Innovation","RECRUITING","Bangkok","10330","Thailand","TH",{"type":44,"coordinates":45},"Point",[46,47],100.50144,13.75398,{"lat":47,"lon":46},[50,52,53],{"name":27,"role":28,"phone":51,"phoneExt":30,"email":31},"66828994433",{"name":33,"role":28,"phone":30,"phoneExt":30,"email":34},{"name":23,"role":24,"phone":30,"phoneExt":30,"email":30},{"type":24,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Somchai Sriplienchan, MD","Executive Director of SEARCH Research Foundation",[58],{"name":59,"class":60},"ViiV Healthcare","INDUSTRY","100117556","phase-3-antiretroviral-therapy-for-acute-and-chronic-hiv-infection-100117556",false,"NCT00796263","Antiretroviral Therapy for Acute and Chronic HIV Infection","AAHIV","Inclusion Criteria:\n\n1. Age ≥ 18 years old\n2. Enrolled in the SEARCH 010 or 013 protocols with documentation of acute or chronic protocol defined HIV-1 infection and chooses to initiate or continue ART\n3. Understand the study and sign informed consent form. Persons who cannot read will have the consent form read and explained to them by a member of the study staff and they can give informed consent by using their thumb print\n4. Availability for follow-up for the planned study duration\n\nExclusion Criteria:\n\n1\\. Persons who have a history of a medical or psychiatric disorder by investigator's interview and physical examination according to standard practices, that in the judgment of the investigator(s), would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent.","ALL","18 Years",{"count":71,"type":72},900,"ESTIMATED","INTERVENTIONAL",[75],"PHASE3","The purpose for this protocol is to provide safe and effective standard ART to SEARCH 010 and SEARCH 013 participants. Participants are enrolled in an acute HIV infection study (SEARCH 010 protocol: 'Establish and characterize an acute HIV infection cohort in a Thai high-risk population') or in a study of chronic HIV infection (SEARCH 013 protocol 'Characteristics of immunity in gut mucosa, spinal fluid, lymph node and blood of HIV negative and HIV positive Thais').",[78,79],"Acute HIV Infection","Chronic HIV Infection",[81,82],"Acute HIV infection","Chronic HIV infection","2025-05-28",{"date":85,"type":86},"2025-06-04","ACTUAL",{"date":88,"type":86},"2009-05-13",{"date":90,"type":72},"2033-06",{"name":5,"class":6},1]